U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H16N6S
Molecular Weight 252.339
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of CIMETIDINE

SMILES

CNC(NCCSCC1=C(C)NC=N1)=NC#N

InChI

InChIKey=AQIXAKUUQRKLND-UHFFFAOYSA-N
InChI=1S/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14)

HIDE SMILES / InChI
Molecular Formula C10H16N6S
Molecular Weight 252.339
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/cdi/cimetidine.html

Cimetidine is a histamine H2-receptor antagonist. It reduces basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin. It is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Cimetidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Cimetidine include an increase in gastric bacterial flora such as nitrate-reducing organisms. Cimetidine binds to an H2-receptor located on the basolateral membrane of the gastric parietal cell, blocking histamine effects. This competitive inhibition results in reduced gastric acid secretion and a reduction in gastric volume and acidity.

CNS Activity

CNS Penetrant
2588
Curator's Comment: Enhanced cimetidine penetration of the blood brain barrier has been demonstrated in patients with liver disease.

Originator

Approval Year

1977
76
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
 70.0 nM [Ki]
Inhibitor
8504
 1.2 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
TAGAMET

Approved Use

Treating and preventing ulcers of the stomach and small intestine, and treating gastroesophageal reflux disease (GERD). It may be used for treating esophagitis (inflammation of the esophagus) caused by acid reflux and certain conditions that cause increased acid secretion (eg, Zollinger-Ellison syndrome).

Launch Date

1995
Primary
Approved
8583
TAGAMET

Approved Use

Treating and preventing ulcers of the stomach and small intestine, and treating gastroesophageal reflux disease (GERD). It may be used for treating esophagitis (inflammation of the esophagus) caused by acid reflux and certain conditions that cause increased acid secretion (eg, Zollinger-Ellison syndrome).

Launch Date

1995
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.056 μg/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/anda/98/75285_Cimetidine.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CIMETIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.22 μg × h/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/anda/98/75285_Cimetidine.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CIMETIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.4 h
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/anda/98/75285_Cimetidine.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CIMETIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
unhealthy, 50 years (range: 22-85 years)
Health Status: unhealthy
Age Group: 50 years (range: 22-85 years)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
Other AEs: Headache, Abdominal pain...
Other AEs:
Headache (2 patients)
Abdominal pain (2 patients)
Nausea (2 patients)
Anorexia (2 patients)
Vomiting (2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
20 g single, oral
Overdose
Dose: 20 g
Route: oral
Route: single
Dose: 20 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/92705
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/92705
Sources:
https://pubmed.ncbi.nlm.nih.gov/92705
3 g 4 times / day multiple, oral
Overdose
Dose: 3 g, 4 times / day
Route: oral
Route: multiple
Dose: 3 g, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/74598
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/74598
Sources:
https://pubmed.ncbi.nlm.nih.gov/74598
300 mg 4 times / day multiple, respiratory
Recommended
Dose: 300 mg, 4 times / day
Route: respiratory
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aa4ee5b-b5be-4a98-5b8c-6f75e2b59e51
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aa4ee5b-b5be-4a98-5b8c-6f75e2b59e51
Sources:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aa4ee5b-b5be-4a98-5b8c-6f75e2b59e51
AEs

AEs

AESignificanceDosePopulation
Abdominal pain 2 patients
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
unhealthy, 50 years (range: 22-85 years)
Health Status: unhealthy
Age Group: 50 years (range: 22-85 years)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
Anorexia 2 patients
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
unhealthy, 50 years (range: 22-85 years)
Health Status: unhealthy
Age Group: 50 years (range: 22-85 years)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
Headache 2 patients
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
unhealthy, 50 years (range: 22-85 years)
Health Status: unhealthy
Age Group: 50 years (range: 22-85 years)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
Nausea 2 patients
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
unhealthy, 50 years (range: 22-85 years)
Health Status: unhealthy
Age Group: 50 years (range: 22-85 years)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
Vomiting 2 patients
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
unhealthy, 50 years (range: 22-85 years)
Health Status: unhealthy
Age Group: 50 years (range: 22-85 years)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2438
inhibitor
2507
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
2153

CYP3A4/5
296

CYP2C19
2057

MATE1
415

OCT2
779

OAT3
747

MATE2
267

OCT1
620
OAT3
391

MATE1
182

MATE2
98
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
OCT2
782
 yes [IC50 110 uM]
OCT1
656
 yes [IC50 149 uM]
CYP1A2
2333
 yes [IC50 200 uM]
CYP2D6
2546
 yes [IC50 210 uM]
CYP3A4/5
357
 yes [IC50 480 uM]
yes (co-administration study)
Comment: Coadministration with midazolam: [AUC(0-12)] and AUC(0-∞) values for midazolam were 507.0 ± 265.1 (40%) and 786.1 ± 365.2 (50%) nmol/mL · h, respectively;
Page: 4.0
OAT3
749
 yes [IC50 79 uM]
CYP2C9
2497
 yes [Inhibition 10 uM]
CYP2C19
2141
 yes [Ki 157.8 uM]
MATE2
267
 yes [Ki 2.1 uM]
MATE1
416
 yes [Ki 3.8 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
MATE1
182
 yes
MATE2
98
 yes
OAT3
391
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:3699
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3699
ChemicalBook
CB31086794
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB31086794
ChemicalBook
CB4229414
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4229414
eMolecules
1107425
https://www.emolecules.com/cgi-bin/more?vid=1107425
eMolecules
19230646
https://www.emolecules.com/cgi-bin/more?vid=19230646
eMolecules
26714830
https://www.emolecules.com/cgi-bin/more?vid=26714830
eMolecules
6208997
https://www.emolecules.com/cgi-bin/more?vid=6208997
eMolecules
901649
https://www.emolecules.com/cgi-bin/more?vid=901649
MolPort
MolPort-001-838-193
https://www.molport.com/shop/molecule-link/MolPort-001-838-193
MolPort
MolPort-003-895-998
https://www.molport.com/shop/molecule-link/MolPort-003-895-998
MolPort
MolPort-016-638-396
https://www.molport.com/shop/molecule-link/MolPort-016-638-396
MolPort
MolPort-020-313-426
https://www.molport.com/shop/molecule-link/MolPort-020-313-426
MolPort
MolPort-042-675-761
https://www.molport.com/shop/molecule-link/MolPort-042-675-761
Selleck Chemicals
Cimetidine(Tagamet)
http://www.selleckchem.com/products/Cimetidine(Tagamet).html
ZINC
ZINC000018115268
http://zinc15.docking.org/substances/ZINC000018115268
PubMed

PubMed

TitleDatePubMed
Involvement of histaminergic receptor mechanisms in the stimulation of NT-3 synthesis in astrocytes.
2011-06
Two cases of h(2)-receptor antagonist hypersensitivity and cross-reactivity.
2011-04
Hepatoprotective, antinociceptive and antioxidant activities of cimetidine, ranitidine and famotidine as histamine H2 receptor antagonists.
2011-02
Gastroprotective mechanisms of Citrus lemon (Rutaceae) essential oil and its majority compounds limonene and β-pinene: involvement of heat-shock protein-70, vasoactive intestinal peptide, glutathione, sulfhydryl compounds, nitric oxide and prostaglandin E₂.
2011-01-15
OCT1 Expression in adipocytes could contribute to increased metformin action in obese subjects.
2011-01
Novel approaches to inhibition of gastric acid secretion.
2010-12
Drug interaction and pharmacist.
2010-07
Cimetidine induces apoptosis in gastric cancer cells in vitro and inhibits tumor growth in vivo.
2010-03
Size-dependent effects of nanoparticles on the activity of cytochrome P450 isoenzymes.
2010-02-01
Immune hemolytic anemia due to cimetidine: the first example of a cimetidine antibody.
2010-02
Bioactivation of lamotrigine in vivo in rat and in vitro in human liver microsomes, hepatocytes, and epidermal keratinocytes: characterization of thioether conjugates by liquid chromatography/mass spectrometry and high field nuclear magnetic resonance spectroscopy.
2010-01
Identification of a novel organic anion transporter mediating carnitine transport in mouse liver and kidney.
2010
Androgen action via testicular peritubular myoid cells is essential for male fertility.
2009-12
Enhanced ERbeta immunoexpression and apoptosis in the germ cells of cimetidine-treated rats.
2009-11-18
Antiulcer and anticonvulsant activity of Croton zambesicus.
2009-10
Ameliorative effects of histamine on spatial memory deficits induced by scopolamine infusion into bilateral dorsal or ventral hippocampus as evaluated by the radial arm maze task.
2009-08
Gastroprotective activity of alkaloid extract and 2-phenylquinoline obtained from the bark of Galipea longiflora Krause (Rutaceae).
2009-07-15
Pharmacokinetics of cimetidine in dogs after oral administration of cimetidine tablets.
2009-06
Ligand diversity of human and chimpanzee CYP3A4: activation of human CYP3A4 by lithocholic acid results from positive selection.
2009-06
Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells.
2009-04
The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity.
2009-03
Contribution of mast cells to the oedema induced by Bothrops moojeni snake venom and a pharmacological assessment of the inflammatory mediators involved.
2009-02-16
Visions of drug discovery. Cimetidine (Tagamet).
2009-02
Inhibitory effects of the antiepileptic drug ethosuximide on G protein-activated inwardly rectifying K+ channels.
2009-02
Ocular surface tumors.
2009-01
Morphological evidences indicate that the interference of cimetidine on the peritubular components is responsible for detachment and apoptosis of Sertoli cells.
2008-05-09
Caki-1 cells as a model system for the interaction of renally secreted drugs with OCT3.
2008
Effect of sodium ozagrel on the activity of rat CYP2D6.
2007-11-14
Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters.
2007-07-15
Cimetidine inhibits epidermal growth factor-induced cell signaling.
2007-03
Cimetidine induces apoptosis of human salivary gland tumor cells.
2007-03
[Usefulness of equations based on serum cystatin C concentration in the study of renal function].
2007
Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H+ antiporter in the kidney.
2006-11
Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2.
2006-08
Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes.
2006-08
Effect of endogenous histamine in the ventral hippocampus on fear memory deficits induced by scopolamine as evaluated by step-through avoidance response in rats.
2006-04-15
Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists.
2006-03
In vitro availability of metformin in presence of h(2) receptor antagonists.
2006-01
Putting theory into practice: James Black, receptor theory and the development of the beta-blockers at ICI, 1958-1978.
2006-01
Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
2006
Cimetidine-induced tubulointerstitial nephritis with both MPO-ANCA and PR3-ANCA.
2005-12
Effects of histamine 2 receptor antagonists on endothelial-neutrophil adhesion and surface expression of endothelial adhesion molecules induced by high glucose levels.
2004-11-01
Decreased histamine H1 receptors in the frontal cortex of brains from patients with chronic schizophrenia.
1991-08-15
Diphenhydramine prevents the haemodynamic changes of cimetidine in ICU patients.
1991-03
Cimetidine inhibits catechol estrogen metabolism in women.
1991-02
Nifedipine versus cimetidine in prevention of stress-induced gastric ulcers in rats.
1991-01-03
Effects of antihistaminics on locomotor activity in mice. Comparison with opiate and amphetamine-induced hyperactivity.
1991
[Cimetidine-induced aplastic anemia complicated with nonbacterial thrombotic endocarditis and cerebral infarction].
1990-12
Hemodynamic effects of H2-receptor antagonists.
1990-11
[Confusion induced by the combination cimetidine-benzodiazepine; apropos of a case report].
1990-01
Patents

Patents

04093621
3
04140783
6
04255425
2
04267337
3
05075291
2
JP2003530301A
2
JP2007008845A
5
JP3292732B2
20
JP4732696B2
68
JPH01299274A
2
JPH0225468A
2
JPH0245416A
2
JPH0276859A
2
JPH08157354A
2
JPH08512055A
14
JPS56104868A
2
JPS57203071A
2
JPS58174370A
2
JPS58188860A
2
JPS5852213A
2
JPS63190872A
2
JPS63192757A
2

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Duodenal Ulcer Parenteral: 300 mg IV or IM every 6 to 8 hours. Alternatively, a continuous IV infusion may be administered at a rate of 37.5 to 50 mg/hour, or up to a maximum rate of 100 mg/hour (2.4 g/day). Oral: 800 mg to 1600 mg once a day at bedtime. Alternatively, dosage regimens of 300 mg four times per day, with meals and at bedtime, or 400 mg twice daily, in the morning and at bedtime, have shown to be effective.
Route of Administration: Other
In Vitro Use Guide
Cimetidine (10(-7)M) inhibited IL-10 production and restored IL-12 secretion in LPS-treated murine DCs.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:10:47 GMT 2025
Edited
by admin
on Mon Mar 31 18:10:47 GMT 2025
Record UNII
80061L1WGD
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACILOC
Preferred Name English
CIMETIDINE
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
CIMETIDINE [MI]
Common Name English
2-CYANO-1-METHYL-3-(2-(((5-METHYLIMIDAZOL-4-YL)METHYL)THIO)ETHYL)-GUANIDINE
Systematic Name English
CIMETIDINE [JAN]
Common Name English
CIMETIDINE [USAN]
Common Name English
BRUMETIDINA
Brand Name English
CIMETIDINE [IARC]
Common Name English
TAGAMET
Brand Name English
CIMAL
Brand Name English
CIMETIDINE [MART.]
Common Name English
ACINIL
Brand Name English
STOMEDINE
Brand Name English
DYSPAMET
Brand Name English
GASTROMET
Common Name English
Cimetidine [WHO-DD]
Common Name English
cimetidine [INN]
Common Name English
CIMETIDINUM [WHO-IP LATIN]
Common Name English
ULCEDIN
Brand Name English
ULCOMEDINA
Common Name English
CIMETIDINE [WHO-IP]
Common Name English
GUANIDINE, N''-CYANO-N-METHYL-N'-(2-(((5-METHYL-1H-IMIDAZOL-4-YL)METHYL)THIO)ETHYL)-
Systematic Name English
CIMETIDINE [HSDB]
Common Name English
SKF-92334
Code English
CIMETIDINE [USP-RS]
Common Name English
ULCIMET
Brand Name English
CIMETIDINE [USP MONOGRAPH]
Common Name English
CIMETIDINE [VANDF]
Common Name English
CIMETIDINE [EP MONOGRAPH]
Common Name English
CIMETIDINE [ORANGE BOOK]
Common Name English
NSC-335308
Code English
Classification Tree Code System Code
NCI_THESAURUS C29702
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
WHO-VATC QA02BA01
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
NDF-RT N0000000151
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
WHO-VATC QA02BA51
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
LIVERTOX NBK548130
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
WHO-ATC A02BA01
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
WHO-ATC A02BA51
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
NDF-RT N0000175784
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
Code System Code Type Description
NSC
335308
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY
INN
3765
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY
CAS
51481-61-9
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY
SMS_ID
100000092793
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY
CHEBI
50362
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY
RS_ITEM_NUM
1134062
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY
NCI_THESAURUS
C374
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY
CHEBI
3699
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY
MESH
D002927
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY
MERCK INDEX
m3552
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY Merck Index
EPA CompTox
DTXSID4020329
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY
EVMPD
SUB06279MIG
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY
WIKIPEDIA
CIMETIDINE
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY
LACTMED
Cimetidine
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY
RXCUI
2541
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY RxNorm
HSDB
3917
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY
ChEMBL
CHEMBL30
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY
FDA UNII
80061L1WGD
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY
IUPHAR
1231
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY
DRUG BANK
DB00501
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
CIMETIDINE
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY Description: A white to off-white powder; odourless or with a faint odour.Solubility: Sparingly soluble in water; very soluble in methanol R.Category: Antiulcer drug.Storage: Cimetidine should be kept in a well-closed container.
PUBCHEM
2756
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY
ECHA (EC/EINECS)
257-232-2
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY
DAILYMED
80061L1WGD
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY
DRUG CENTRAL
645
Created by admin on Mon Mar 31 18:10:47 GMT 2025 , Edited by admin on Mon Mar 31 18:10:47 GMT 2025
PRIMARY
Related Record Type Details
OCT-3
TRANSPORTER -> SUBSTRATE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
OCT-1
TRANSPORTER -> SUBSTRATE
OCT-1
TRANSPORTER -> INHIBITOR
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
OAT-3
TRANSPORTER -> INHIBITOR
MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1
TRANSPORTER -> SUBSTRATE
Vmax
MATE-2
TRANSPORTER -> SUBSTRATE
Vmax
CYTOCHROME P450 2D6
METABOLIC ENZYME -> INHIBITOR
MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1
TRANSPORTER -> SUBSTRATE
Km
OAT-3
TRANSPORTER -> SUBSTRATE
OCT-2
TRANSPORTER -> SUBSTRATE
MATE-2
TRANSPORTER -> SUBSTRATE
Km
CYTOCHROME P450 1A2
METABOLIC ENZYME -> INHIBITOR
MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1
TRANSPORTER -> INHIBITOR
OCT-2
TRANSPORTER -> INHIBITOR
MATE-2
TRANSPORTER -> INHIBITOR
HISTAMINE H1 RECEPTOR
TARGET -> AGONIST
IC50
HISTAMINE H2 RECEPTOR
TARGET -> INHIBITOR
BINDING
IC50
Related Record Type Details
Structure of CIMETIDINE HYDROXYMETHYL
METABOLITE -> PARENT
Structure of CIMETIDINE SULFOXIDE
METABOLITE -> PARENT
MAJOR
URINE
Related Record Type Details
Structure of N-Methyl-N?-[2-[[(4-methyl-1H-imidazol-5-yl)methyl]thio]ethyl]guanidine
IMPURITY -> PARENT
Structure of 1-Cyano-3-[2-[2-[(N-cyano-N?-methylcarbamimidoyl)amino]ethyldisulfanyl]ethyl]-2-methylguanidine
IMPURITY -> PARENT
Structure of 2-CYANO-1,3-DIMETHYLGUANIDINE
IMPURITY -> PARENT
Structure of N-Cyano-N?,N??-bis[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]guanidine
IMPURITY -> PARENT
Related Record Type Details
Structure of CIMETIDINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966